LENSAR, Inc. (LNSR)

NASDAQ: LNSR · Real-Time Price · USD
14.13
-0.01 (-0.07%)
At close: Mar 28, 2025, 4:00 PM
14.12
-0.01 (-0.07%)
After-hours: Mar 28, 2025, 7:49 PM EDT
-0.07%
Market Cap 166.59M
Revenue (ttm) 53.49M
Net Income (ttm) -31.40M
Shares Out 11.79M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 172,381
Open 14.17
Previous Close 14.14
Day's Range 14.13 - 14.20
52-Week Range 2.67 - 17.31
Beta 0.62
Analysts Hold
Price Target 15.00 (+6.16%)
Earnings Date May 8, 2025

About LNSR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment s... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2004
Employees 140
Stock Exchange NASDAQ
Ticker Symbol LNSR
Full Company Profile

Financial Performance

In 2024, LENSAR's revenue was $53.49 million, an increase of 26.87% compared to the previous year's $42.16 million. Losses were -$31.40 million, 118.3% more than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for LNSR stock is "Hold" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(6.16% upside)
Analyst Consensus: Hold
Stock Forecasts

News

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

Other symbols: ALC
3 days ago - Business Wire

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors gran...

26 days ago - GlobeNewsWire

LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive...

4 weeks ago - Seeking Alpha

LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385...

4 weeks ago - GlobeNewsWire

LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025

ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

5 weeks ago - GlobeNewsWire

Medical Devices Firm Lensar Surges Ahead On Robotic Technology

LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract ...

7 weeks ago - Seeking Alpha

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

4 months ago - GlobeNewsWire

LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive ...

5 months ago - Seeking Alpha

LENSAR Reports Third Quarter 2024 Results and Provides Business Update

24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024

5 months ago - GlobeNewsWire

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

5 months ago - GlobeNewsWire

One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems

ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

6 months ago - GlobeNewsWire

LENSAR to Participate in Two Upcoming Investor Conferences

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...

7 months ago - Business Wire

LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call P...

8 months ago - Seeking Alpha

LENSAR Reports Second Quarter 2024 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...

8 months ago - Business Wire

LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...

8 months ago - Business Wire

LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...

8 months ago - Business Wire

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

11 months ago - Business Wire

LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participant...

11 months ago - Seeking Alpha

LENSAR Reports First Quarter 2024 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

11 months ago - Business Wire

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

11 months ago - Business Wire

LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Conference Call March 4, 2024 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - ...

1 year ago - Seeking Alpha

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

1 year ago - Business Wire

LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

1 year ago - Business Wire

LENSAR, Inc. (LNSR) Q3 2023 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Ca...

1 year ago - Seeking Alpha

LENSAR Reports Third Quarter 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

1 year ago - Business Wire